EMA multi-stakeholder workshop on the clinical evaluation of therapeutic radiopharmaceuticals in oncology, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 November 2025, 09:00 (CET) to 17 November 2025, 15:00 (CET)

Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 July 2025, 10:00 (CEST) to 8 July 2025, 11:00 (CEST)

Network Data Steering Group workplan 2025-2028

Medicinal products for human use: monthly figures - June 2025

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products - Revision 1

Requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) - Scientific guideline

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 9, Status: Authorised

Guideline on the requirements for demonstrating therapeutic equivalence between orally inhaled products (OIP) for asthma and chronic obstructive pulmonary disease (COPD) - Revision 2

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products - Revision 1

Annex to 21-24 July 2025 CHMP Agenda